Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation

Abstract Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic strategies to improve cognition in schizophrenia have either used medications (collectively referred to as ‘cognitive-enhancing drugs’...

Full description

Saved in:
Bibliographic Details
Published inEuropean neuropsychopharmacology Vol. 23; no. 8; pp. 790 - 798
Main Authors Michalopoulou, Panayiota G, Lewis, Shôn W, Wykes, Til, Jaeger, Judith, Kapur, Shitij
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2013
Subjects
Animals
Cognition - drug effects
Cognition Disorders - drug therapy
Cognition Disorders - etiology
Cognition Disorders - rehabilitation
Cognitive ability
Cognitive impairment
Cognitive remediation
Cognitive-enhancing drugs
Combination of cognitive remediation with cognitive-enhancing drugs
Combined Modality Therapy
Evidence-Based Medicine
Humans
Internal Medicine
Performance-Enhancing Substances - therapeutic use
Psychiatry
Remedial Teaching
Schizophrenia
Schizophrenia - physiopathology
Schizophrenia
Combination of cognitive remediation with cognitive-enhancing drugs
Cognitive-enhancing drugs
Cognitive remediation
Cognitive impairment
Online AccessGet full text

Cover

Abstract Abstract Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic strategies to improve cognition in schizophrenia have either used medications (collectively referred to as ‘cognitive-enhancing drugs’ in this article) or non-pharmacological training approaches (‘cognitive remediation’). Cognitive-enhancing drugs have not as yet been successful and cognitive remediation has shown modest success. Therefore, we may need to explore new therapeutic paradigms to improve cognition in schizophrenia. The optimal approach may require a combination of cognitive-enhancing drugs with cognitive remediation. We review the available data from animal and human studies that provide the conceptual basis, proof-of-concept and illustrations of success of such combination strategies in experimental and clinical paradigms in other conditions. We address the major design issues relevant to the choice of the cognitive-enhancing drugs and cognitive remediation, as well as the timing and the duration of the intervention as will be relevant for schizophrenia. Finally, we address the practical realities of the development and testing of such combined approaches in the real-world clinical situation and conclude that while scientifically attractive, there are several practical difficulties to be overcome for this approach to be clinically feasible.
AbstractList Abstract Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic strategies to improve cognition in schizophrenia have either used medications (collectively referred to as ‘cognitive-enhancing drugs’ in this article) or non-pharmacological training approaches (‘cognitive remediation’). Cognitive-enhancing drugs have not as yet been successful and cognitive remediation has shown modest success. Therefore, we may need to explore new therapeutic paradigms to improve cognition in schizophrenia. The optimal approach may require a combination of cognitive-enhancing drugs with cognitive remediation. We review the available data from animal and human studies that provide the conceptual basis, proof-of-concept and illustrations of success of such combination strategies in experimental and clinical paradigms in other conditions. We address the major design issues relevant to the choice of the cognitive-enhancing drugs and cognitive remediation, as well as the timing and the duration of the intervention as will be relevant for schizophrenia. Finally, we address the practical realities of the development and testing of such combined approaches in the real-world clinical situation and conclude that while scientifically attractive, there are several practical difficulties to be overcome for this approach to be clinically feasible.
Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic strategies to improve cognition in schizophrenia have either used medications (collectively referred to as 'cognitive-enhancing drugs' in this article) or non-pharmacological training approaches ('cognitive remediation'). Cognitive-enhancing drugs have not as yet been successful and cognitive remediation has shown modest success. Therefore, we may need to explore new therapeutic paradigms to improve cognition in schizophrenia. The optimal approach may require a combination of cognitive-enhancing drugs with cognitive remediation. We review the available data from animal and human studies that provide the conceptual basis, proof-of-concept and illustrations of success of such combination strategies in experimental and clinical paradigms in other conditions. We address the major design issues relevant to the choice of the cognitive-enhancing drugs and cognitive remediation, as well as the timing and the duration of the intervention as will be relevant for schizophrenia. Finally, we address the practical realities of the development and testing of such combined approaches in the real-world clinical situation and conclude that while scientifically attractive, there are several practical difficulties to be overcome for this approach to be clinically feasible.
Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic strategies to improve cognition in schizophrenia have either used medications (collectively referred to as acognitive-enhancing drugsa in this article) or non-pharmacological training approaches (acognitive remediationa). Cognitive-enhancing drugs have not as yet been successful and cognitive remediation has shown modest success. Therefore, we may need to explore new therapeutic paradigms to improve cognition in schizophrenia. The optimal approach may require a combination of cognitive-enhancing drugs with cognitive remediation. We review the available data from animal and human studies that provide the conceptual basis, proof-of-concept and illustrations of success of such combination strategies in experimental and clinical paradigms in other conditions. We address the major design issues relevant to the choice of the cognitive-enhancing drugs and cognitive remediation, as well as the timing and the duration of the intervention as will be relevant for schizophrenia. Finally, we address the practical realities of the development and testing of such combined approaches in the real-world clinical situation and conclude that while scientifically attractive, there are several practical difficulties to be overcome for this approach to be clinically feasible.
Author Michalopoulou, Panayiota G
Lewis, Shôn W
Wykes, Til
Jaeger, Judith
Kapur, Shitij
Author_xml – sequence: 1
  fullname: Michalopoulou, Panayiota G
– sequence: 2
  fullname: Lewis, Shôn W
– sequence: 3
  fullname: Wykes, Til
– sequence: 4
  fullname: Jaeger, Judith
– sequence: 5
  fullname: Kapur, Shitij
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23619163$$D View this record in MEDLINE/PubMed
BookMark eNqNUsuKFDEUDTLi9Iz-gmbppto8Ko9yIQyDLxhwYQvuQip1uyttVdImVSPt15ui2xHcKFwSuDnnXHLOvUIXIQZA6AUla0qofLVfw5xKqxxrRihfk1KUPUIrqhWvlJbsAq1Iw-qqUerrJbrKeU8IFZw3T9Al45I2VPIVOm4S2MmHHfbjwfoEHXZxF_zkY8A-4Ox6_zMe-gTB29d40wN2NgPexlSAY-vDwj1T7qGC0Nvgll6X5l3GP_zU_3nGCUbovF3Un6LHWztkeHa-r9GXd283tx-qu0_vP97e3FWuFs1UcdY1TFgrnXactKR8QjEtXadVqx0Iy6hot1Q6oepOccK1dlbzmgjNWskpv0YvT7qHFL_PkCcz-uxgGGyAOGdDBSFKUaXkv6E1k6LghS5QdYK6FHNOsDWH5EebjoYSs0Rk9uYhIrNEZEgpygrz-XnI3BYzHni_MymAmxMAiiv3HpLJzkNwxbgEbjJd9P8x5M1fGm4oUTk7fIMj5H2cUyimG2oyM8R8XjZlWRTKi79USP4LFBm_Eg
CitedBy_id crossref_primary_10_1016_j_pbb_2016_07_001
crossref_primary_10_1038_nrdp_2015_67
crossref_primary_10_1016_S2215_0366_15_00004_8
crossref_primary_10_1016_j_cobeha_2015_05_005
crossref_primary_10_3389_fpsyt_2018_00461
crossref_primary_10_2217_bmm_13_135
crossref_primary_10_1002_gps_4329
crossref_primary_10_1016_j_brs_2016_12_013
crossref_primary_10_1371_journal_pone_0254695
crossref_primary_10_1016_j_ijpsycho_2014_03_008
crossref_primary_10_1093_brain_awx170
crossref_primary_10_1016_j_schres_2018_04_025
crossref_primary_10_1155_2016_8213165
crossref_primary_10_1093_schbul_sbv111
crossref_primary_10_4103_njbcs_njbcs_9_20
crossref_primary_10_1016_j_jep_2021_114864
crossref_primary_10_1016_j_euroneuro_2015_03_009
crossref_primary_10_3389_fpsyt_2014_00103
crossref_primary_10_1016_j_schres_2016_11_044
crossref_primary_10_1177_2045125317737003
Cites_doi 10.1093/oxfordjournals.schbul.a033430
10.1016/j.schres.2004.12.019
10.1016/0006-8993(94)91404-4
10.1002/ana.410230117
10.1016/j.biopsych.2009.02.017
10.1146/annurev.clinpsy.3.022806.091529
10.1002/ana.21597
10.1016/j.biopsych.2008.01.012
10.1016/j.neuropharm.2012.07.011
10.1016/j.schres.2011.05.029
10.1002/ana.20125
10.1016/S0079-6123(09)17534-9
10.1037/0033-2909.133.5.833
10.1016/0006-8993(85)91135-7
10.1006/exnr.1997.6581
10.1176/ajp.155.8.1080
10.1007/s00213-003-1672-y
10.1001/archgenpsychiatry.2010.63
10.1038/npp.2010.158
10.1176/appi.ajp.2007.07050724
10.1176/appi.ajp.2009.09020264
10.1111/j.1600-0404.2006.00728.x
10.1016/S0003-9993(98)90169-1
10.1016/S0165-0173(97)00004-0
10.1002/ana.10056
10.1161/hs0901.095720
10.1093/schbul/sbm083
10.1016/j.neuron.2012.06.016
10.1038/sj.mp.4001907
10.1176/appi.ajp.2010.10060855
10.1002/hup.1118
10.1523/JNEUROSCI.18-07-02740.1998
10.1016/j.coph.2005.09.007
10.4088/JCP.08m04666yel
10.4088/JCP.v66n0705
10.1016/j.schres.2011.05.004
10.1038/sj.npp.1301534
10.1016/j.schres.2012.03.020
10.1126/science.1214592
10.1007/s00213-011-2472-4
10.1093/schbul/sbp115
10.1176/ajp.148.1.78
10.1016/S0140-6736(01)05966-9
10.1001/archgenpsychiatry.2010.105
10.1016/0006-8993(84)91437-9
10.1038/sj.npp.1301444
10.1007/s00213-008-1285-6
10.1161/01.STR.26.12.2254
10.1001/archpsyc.64.5.532
10.1038/npp.2011.195
10.1523/JNEUROSCI.11-07-01907.1991
10.1038/sj.npp.1300464
10.1007/978-3-642-25758-2_4
10.1093/schbul/sbp129
10.1007/7854_2010_39
10.1126/science.1150516
10.1016/j.tins.2006.07.007
10.1093/schbul/sbr064
10.1126/science.7100929
10.1038/npp.2011.251
10.1016/j.schres.2008.08.012
10.1038/sj.npp.1300457
10.1176/appi.ajp.2012.11091337
10.1016/j.apmr.2010.11.015
10.1037/h0075094
10.1001/archgenpsychiatry.2009.91
ContentType Journal Article
Copyright Elsevier B.V. and ECNP
2013 Elsevier B.V. and ECNP
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.
Copyright_xml – notice: Elsevier B.V. and ECNP
– notice: 2013 Elsevier B.V. and ECNP
– notice: Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7TK
DOI 10.1016/j.euroneuro.2013.03.012
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitleList
MEDLINE - Academic
MEDLINE

Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-7862
EndPage 798
ExternalDocumentID 10_1016_j_euroneuro_2013_03_012
23619163
S0924977X13001156
1_s2_0_S0924977X13001156
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0701748
– fundername: Medical Research Council
  grantid: G0400999
– fundername: Department of Health
  grantid: PB-PG-0807-14002
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AACTN
AADFP
AAEDT
AAEDW
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXKI
AAXLA
AAXUO
ABBQC
ABCQJ
ABFNM
ABFRF
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ACXNI
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRLJ
AKRWK
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDW
HMK
HMO
HMQ
HMT
HVGLF
HZ~
IHE
J1W
KOM
LX8
M29
M2V
M34
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OGGZJ
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPT
SSB
SSH
SSN
SSP
SSY
SSZ
T5K
UNMZH
WUQ
XPP
Z5R
~G-
AADPK
AAIAV
AATCM
ABLVK
ABYKQ
AFYLN
AJBFU
EFLBG
LCYCR
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7TK
ID FETCH-LOGICAL-c459t-32d925aa6c8c30b00017286cd87b8ce5a215bf16c574d730388ca8340582b6313
IEDL.DBID .~1
ISSN 0924-977X
IngestDate Fri Oct 25 06:59:54 EDT 2024
Sat Oct 05 05:21:31 EDT 2024
Thu Sep 26 17:17:17 EDT 2024
Sat Nov 02 12:30:35 EDT 2024
Fri Feb 23 02:26:21 EST 2024
Tue Oct 15 23:01:43 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Schizophrenia
Combination of cognitive remediation with cognitive-enhancing drugs
Cognitive-enhancing drugs
Cognitive remediation
Cognitive impairment
Language English
License Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-32d925aa6c8c30b00017286cd87b8ce5a215bf16c574d730388ca8340582b6313
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Feature-1
PMID 23619163
PQID 1426515058
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1500771776
proquest_miscellaneous_1426515058
crossref_primary_10_1016_j_euroneuro_2013_03_012
pubmed_primary_23619163
elsevier_sciencedirect_doi_10_1016_j_euroneuro_2013_03_012
elsevier_clinicalkeyesjournals_1_s2_0_S0924977X13001156
PublicationCentury 2000
PublicationDate 2013-08-01
PublicationDateYYYYMMDD 2013-08-01
PublicationDate_xml – month: 08
  year: 2013
  text: 2013-08-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle European neuropsychopharmacology
PublicationTitleAlternate Eur Neuropsychopharmacol
PublicationYear 2013
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Knecht, Breitenstein, Bushuven, Wailke, Kamping, Floel, Zwitserlood, Ringelstein (bib42) 2004; 56
Dickinson, Tenhula, Morris, Brown, Peer, Spencer, Li, Gold, Bellack (bib16) 2010; 167
Wykes, Reeder, Huddy, Taylor, Wood, Chirasim, Kontis, Landau (bib75) 2012; 138
Feeney, Hovda (bib22) 1985; 342
Turner, Clark, Pomarol-Clotet, McKenna, Robbins, Sahakian (bib66) 2004; 29
Lee, Dvorak, Kao, Duffy, Scharfman, Fenton (bib44) 2012; 75
Swerdlow (bib64) 2011; 130
Sandi, Rose (bib58) 1994; 647
Bütefisch, Davis, Sawaki, Waldvogel, Classen, Kopylev, Cohen (bib10) 2002; 51
Levkovitz, Mendlovich, Riwkes, Braw, Levkovitch-Verbin, Gal, Fennig, Treves, Kron (bib45) 2010; 71
Chou, Twamley, Swerdlow (bib11) 2012; 213
Grade, Redford, Chrostowski, Toussaint, Blackwell (bib29) 1998; 79
National Institute for Health and Clinical Excellence (NICE) 2009. National Collaborating Centre for Mental Health: Schizophrenia: Core interventions in the treatment and management of schizophrenia in the primary and secondary care. London.
Hebb (bib35) 1949
Feeney, Gonzalez, Law (bib21) 1982; 217
Ingvar, Ambros-Ingerson, Davis, Granger, Kessler, Rogers, Schehr, Lynch (bib37) 1997; 146
Platz, Kim, Engel, Pinkowski, Eickhof, Kutzner (bib56) 2005; 23
Johnson, Kotermanski (bib39) 2006; 6
Eack, Hogarty, Cho, Prasad, Greenwald, Hogarty, Keshavan (bib18) 2010; 67
Fawcett (bib20) 2009; 175
Norberg, Krystal, Tolin (bib53) 2008; 63
Sonde, Lokk (bib63) 2007; 115
Scoriels, Jones, Sahakian (bib61) 2013; 64
Reichenberg, Harvey (bib57) 2007; 133
Lynch, Gall (bib47) 2006; 29
Minzenberg, Carter (bib50) 2007; 33
Pietrzak, Snyder, Maruff (bib55) 2010; 25
Floresco, Jentsch (bib23) 2011; 36
Hovda, Fenney (bib36) 1984; 298
Sevy, Rosenthal, Alvir, Meyer, Visweswaraiah, Gunduz-Bruce, Schooler (bib62) 2005; 66
Hampson, Rogers, Lynch, Deadwyler (bib33) 1998; 18
Scheidtmann, Fries, Müller, Koenig (bib59) 2001; 358
Barch (bib2) 2010; 4
Cicerone, Langenbahn, Braden, Malec, Kalmar, Fraas, Felicetti, Laatsch, Harley, Bergquist, Azulay, Cantor, Ashman (bib12) 2011; 92
Wykes, Brammer, Mellers, Bray, Reeder, Williams, Corner (bib72) 2002; 181
Jaskiw, Popli (bib38) 2004; 171
Buchanan, Conley, Dickinson, Ball, Feldman, Gold, McMahon (bib8) 2008; 165
Scoriels, Barnett, Soma, Sahakian, Jones (bib60) 2012; 220
Keefe, Buchanan, Marder, Schooler, Dugar, Zivkov, Stewart (bib41) 2011
Buchanan, Freedman, Javitt, Abi-Dargham, Lieberman (bib9) 2007; 33
Crisostomo, Duncan, Propst, Dawson, Davis (bib13) 1988; 23
Guo, Zhai, Liu, Fang, Wang, Wang, Hu, Sun, Lv, Lu, Ma, He, Guo, Xie, Wu, Xue, Chen, Twamley, Jin, Zhao (bib32) 2010; 67
Green, Kern, Braff, Mintz (bib30) 2000; 26
Minzenberg, Laird, Thelen, Carter, Glahn (bib51) 2009; 66
Barch, Carter (bib3) 2005; 77
Goff, Cather, Gottlieb, Evins, Walsh, Raeke, Otto, Schoenfeld, Green (bib24) 2008; 106
Swerdlow (bib65) 2012; 37
Ehrenreich, Hinze-Selch, Stawicki, Aust, Knolle-Veentjer, Wilms, Heinz, Erdag, Jahn, Degner, Ritzen, Mohr, Wagner, Schneider, Bohn, Huber, Czernik, Pollmacher, Maier, Siren, Klosterkotter, Falkai, Ruther, Aldenhoff, Krampe (bib19) 2007; 12
Goldberg, Bigelow, Weinberger, Daniel, Kleinman (bib27) 1991; 148
Vinogradov, Fisher, Holland, Shelly, Wolkowitz, Mellon (bib68) 2009; 66
Harvey, Howanitz, Parrella, White, Davidson, Mohs, Hoblyn, Davis (bib34) 1998; 155
Daniel, Weinberger, Jones, Zigun, Coppola, Handel, Bigelow, Goldberg, Berman, Kleinman (bib14) 1991; 11
Lashley (bib43) 1917; 1
Wykes, Huddy, Cellard, McGurk, Czobor (bib73) 2011; 168
Breitenstein, Wailke, Bushuven, Kamping, Zwitserlood, Ringelstein, Knecht (bib7) 2004; 29
Berthier, Green, Lara, Higueras, Barbancho, Dávila, Pulvermüller (bib4) 2009; 65
Green (bib31) 2007; 3
Alvarez-Jiménez, Parker, Hetrick, McGorry, Gleeson (bib1) 2011; 37
Vetencourt, Sale, Viegi, Baroncelli, De Pasquale, O'Leary, Castren, Maffei, L. (bib67) 2008; 320
Karpova, Pickenhagen, Lindholm, Tiraboschi, Kulesskaya, Ãgustsdottir, Antila, Popova, Akamine, Sullivan, Hen, Drew, Castren (bib40) 2011; 334
Goff (bib26) 2012; 38
Bowie, Harvey (bib5) 2006; 7
Wykes, Spaulding (bib74) 2011; 37
Dixon, Dickerson, Bellack, Bennett, Dickinson, Goldberg, Lehman, Tenhula, Calmes, Pasillas, Peer, Kreyenbuhl (bib17) 2010; 36
Goff, Lamberti, Leon, Green, Miller, Patel, Manschreck, Freudenreich, Johnson (bib25) 2008; 33
Dickinson, Ramsey, Gold (bib15) 2007; 64
Vinogradov, Fisher, de Villers-Sidani (bib69) 2012; 37
Walker-Batson, Curtis, Natarajan, Ford, Dronkers, Salmeron, Lai, Unwin (bib70) 2001; 32
Gottlieb, Cather, Shanahan, Creedon, Macklin, Goff (bib28) 2011; 131
Lupien, McEwen (bib46) 1997; 24
Bowie, McGurk, Mausbach, Patterson, Harvey (bib6) 2012; 169
Walker-Batson, Smith, Curtis, Unwin, Greenlee (bib71) 1995; 26
McGaugh, Roozendaal (bib49) 2009; 202
Marder (bib48) 2000
Alvarez-Jiménez (10.1016/j.euroneuro.2013.03.012_bib1) 2011; 37
Goldberg (10.1016/j.euroneuro.2013.03.012_bib27) 1991; 148
Dickinson (10.1016/j.euroneuro.2013.03.012_bib16) 2010; 167
Minzenberg (10.1016/j.euroneuro.2013.03.012_bib51) 2009; 66
Goff (10.1016/j.euroneuro.2013.03.012_bib25) 2008; 33
Keefe (10.1016/j.euroneuro.2013.03.012_bib41) 2011
Vetencourt (10.1016/j.euroneuro.2013.03.012_bib67) 2008; 320
Walker-Batson (10.1016/j.euroneuro.2013.03.012_bib70) 2001; 32
Vinogradov (10.1016/j.euroneuro.2013.03.012_bib69) 2012; 37
Walker-Batson (10.1016/j.euroneuro.2013.03.012_bib71) 1995; 26
Wykes (10.1016/j.euroneuro.2013.03.012_bib72) 2002; 181
Gottlieb (10.1016/j.euroneuro.2013.03.012_bib28) 2011; 131
Green (10.1016/j.euroneuro.2013.03.012_bib31) 2007; 3
Sonde (10.1016/j.euroneuro.2013.03.012_bib63) 2007; 115
Cicerone (10.1016/j.euroneuro.2013.03.012_bib12) 2011; 92
Breitenstein (10.1016/j.euroneuro.2013.03.012_bib7) 2004; 29
10.1016/j.euroneuro.2013.03.012_bib52
Knecht (10.1016/j.euroneuro.2013.03.012_bib42) 2004; 56
Fawcett (10.1016/j.euroneuro.2013.03.012_bib20) 2009; 175
Karpova (10.1016/j.euroneuro.2013.03.012_bib40) 2011; 334
Norberg (10.1016/j.euroneuro.2013.03.012_bib53) 2008; 63
Scheidtmann (10.1016/j.euroneuro.2013.03.012_bib59) 2001; 358
Grade (10.1016/j.euroneuro.2013.03.012_bib29) 1998; 79
Ehrenreich (10.1016/j.euroneuro.2013.03.012_bib19) 2007; 12
Marder (10.1016/j.euroneuro.2013.03.012_bib48) 2000
Goff (10.1016/j.euroneuro.2013.03.012_bib24) 2008; 106
Hampson (10.1016/j.euroneuro.2013.03.012_bib33) 1998; 18
Levkovitz (10.1016/j.euroneuro.2013.03.012_bib45) 2010; 71
Dixon (10.1016/j.euroneuro.2013.03.012_bib17) 2010; 36
Wykes (10.1016/j.euroneuro.2013.03.012_bib73) 2011; 168
Lupien (10.1016/j.euroneuro.2013.03.012_bib46) 1997; 24
Reichenberg (10.1016/j.euroneuro.2013.03.012_bib57) 2007; 133
Buchanan (10.1016/j.euroneuro.2013.03.012_bib9) 2007; 33
Wykes (10.1016/j.euroneuro.2013.03.012_bib75) 2012; 138
Berthier (10.1016/j.euroneuro.2013.03.012_bib4) 2009; 65
Buchanan (10.1016/j.euroneuro.2013.03.012_bib8) 2008; 165
Hebb (10.1016/j.euroneuro.2013.03.012_bib35) 1949
Pietrzak (10.1016/j.euroneuro.2013.03.012_bib55) 2010; 25
Sandi (10.1016/j.euroneuro.2013.03.012_bib58) 1994; 647
McGaugh (10.1016/j.euroneuro.2013.03.012_bib49) 2009; 202
Chou (10.1016/j.euroneuro.2013.03.012_bib11) 2012; 213
Swerdlow (10.1016/j.euroneuro.2013.03.012_bib65) 2012; 37
Harvey (10.1016/j.euroneuro.2013.03.012_bib34) 1998; 155
Sevy (10.1016/j.euroneuro.2013.03.012_bib62) 2005; 66
Barch (10.1016/j.euroneuro.2013.03.012_bib3) 2005; 77
Barch (10.1016/j.euroneuro.2013.03.012_bib2) 2010; 4
Ingvar (10.1016/j.euroneuro.2013.03.012_bib37) 1997; 146
Bowie (10.1016/j.euroneuro.2013.03.012_bib6) 2012; 169
Green (10.1016/j.euroneuro.2013.03.012_bib30) 2000; 26
Vinogradov (10.1016/j.euroneuro.2013.03.012_bib68) 2009; 66
Johnson (10.1016/j.euroneuro.2013.03.012_bib39) 2006; 6
Crisostomo (10.1016/j.euroneuro.2013.03.012_bib13) 1988; 23
Scoriels (10.1016/j.euroneuro.2013.03.012_bib60) 2012; 220
Feeney (10.1016/j.euroneuro.2013.03.012_bib22) 1985; 342
Goff (10.1016/j.euroneuro.2013.03.012_bib26) 2012; 38
Jaskiw (10.1016/j.euroneuro.2013.03.012_bib38) 2004; 171
Bütefisch (10.1016/j.euroneuro.2013.03.012_bib10) 2002; 51
Guo (10.1016/j.euroneuro.2013.03.012_bib32) 2010; 67
Eack (10.1016/j.euroneuro.2013.03.012_bib18) 2010; 67
Feeney (10.1016/j.euroneuro.2013.03.012_bib21) 1982; 217
Lynch (10.1016/j.euroneuro.2013.03.012_bib47) 2006; 29
Minzenberg (10.1016/j.euroneuro.2013.03.012_bib50) 2007; 33
Wykes (10.1016/j.euroneuro.2013.03.012_bib74) 2011; 37
Bowie (10.1016/j.euroneuro.2013.03.012_bib5) 2006; 7
Dickinson (10.1016/j.euroneuro.2013.03.012_bib15) 2007; 64
Lashley (10.1016/j.euroneuro.2013.03.012_bib43) 1917; 1
Scoriels (10.1016/j.euroneuro.2013.03.012_bib61) 2013; 64
Daniel (10.1016/j.euroneuro.2013.03.012_bib14) 1991; 11
Swerdlow (10.1016/j.euroneuro.2013.03.012_bib64) 2011; 130
Lee (10.1016/j.euroneuro.2013.03.012_bib44) 2012; 75
Floresco (10.1016/j.euroneuro.2013.03.012_bib23) 2011; 36
Hovda (10.1016/j.euroneuro.2013.03.012_bib36) 1984; 298
Platz (10.1016/j.euroneuro.2013.03.012_bib56) 2005; 23
Turner (10.1016/j.euroneuro.2013.03.012_bib66) 2004; 29
References_xml – year: 1949
  ident: bib35
  article-title: The Organization of Behavior: A Neuropsychological Review
  contributor:
    fullname: Hebb
– volume: 171
  start-page: 365
  year: 2004
  end-page: 374
  ident: bib38
  article-title: A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications
  publication-title: Psychopharmacology (Berl.)
  contributor:
    fullname: Popli
– volume: 37
  start-page: 310
  year: 2012
  end-page: 311
  ident: bib65
  article-title: Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Swerdlow
– volume: 106
  start-page: 320
  year: 2008
  end-page: 327
  ident: bib24
  article-title: Once-weekly
  publication-title: Schizophr. Res.
  contributor:
    fullname: Green
– volume: 3
  start-page: 159
  year: 2007
  end-page: 180
  ident: bib31
  article-title: Stimulating the development of drug treatments to improve cognition in schizophrenia
  publication-title: Annu. Rev. Clin. Psychol.
  contributor:
    fullname: Green
– volume: 334
  start-page: 1731
  year: 2011
  end-page: 1734
  ident: bib40
  article-title: Fear erasure in mice requires synergy between antidepressant drugs and extinction training
  publication-title: Science
  contributor:
    fullname: Castren
– volume: 26
  start-page: 119
  year: 2000
  end-page: 136
  ident: bib30
  article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Mintz
– volume: 65
  start-page: 577
  year: 2009
  end-page: 585
  ident: bib4
  article-title: Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia
  publication-title: Ann. Neurol.
  contributor:
    fullname: Pulvermüller
– volume: 131
  start-page: 69
  year: 2011
  end-page: 74
  ident: bib28
  article-title: -cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
  publication-title: Schizophr. Res.
  contributor:
    fullname: Goff
– volume: 79
  start-page: 1047
  year: 1998
  end-page: 1050
  ident: bib29
  article-title: Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study
  publication-title: Arch. Phys. Med. Rehabil.
  contributor:
    fullname: Blackwell
– volume: 29
  start-page: 1704
  year: 2004
  end-page: 1714
  ident: bib7
  article-title: -amphetamine boosts language learning independent of its cardiovascular and motor arousing effects
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Knecht
– volume: 64
  start-page: 168
  year: 2013
  end-page: 184
  ident: bib61
  article-title: Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain
  publication-title: Neuropharmacology
  contributor:
    fullname: Sahakian
– volume: 71
  start-page: 138
  year: 2010
  end-page: 149
  ident: bib45
  article-title: A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Kron
– volume: 4
  start-page: 43
  year: 2010
  end-page: 96
  ident: bib2
  article-title: Pharmacological strategies for enhancing cognition in schizophrenia
  publication-title: Curr. Top. Behav. Neurosci.
  contributor:
    fullname: Barch
– year: 2011
  ident: bib41
  article-title: Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Stewart
– volume: 220
  start-page: 249
  year: 2012
  end-page: 258
  ident: bib60
  article-title: Effects of modafinil on cognitive functions in first episode psychosis
  publication-title: Psychopharmacology (Berl.)
  contributor:
    fullname: Jones
– volume: 51
  start-page: 59
  year: 2002
  end-page: 68
  ident: bib10
  article-title: Modulation of use-dependent plasticity by
  publication-title: Ann. Neurol.
  contributor:
    fullname: Cohen
– volume: 12
  start-page: 206
  year: 2007
  end-page: 220
  ident: bib19
  article-title: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin
  publication-title: Mol. Psychiatry
  contributor:
    fullname: Krampe
– volume: 29
  start-page: 554
  year: 2006
  end-page: 562
  ident: bib47
  article-title: Ampakines and the threefold path to cognitive enhancement
  publication-title: Trends Neurosci.
  contributor:
    fullname: Gall
– volume: 37
  start-page: S80
  year: 2011
  end-page: S90
  ident: bib74
  article-title: Thinking about the future cognitive remediation therapy—what works and could we do better?
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Spaulding
– volume: 77
  start-page: 43
  year: 2005
  end-page: 58
  ident: bib3
  article-title: Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
  publication-title: Schizophr. Res.
  contributor:
    fullname: Carter
– volume: 169
  start-page: 710
  year: 2012
  end-page: 718
  ident: bib6
  article-title: Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Harvey
– volume: 1
  start-page: 141
  year: 1917
  end-page: 169
  ident: bib43
  article-title: The effects of strychnine and caffeine upon the rate of learning
  publication-title: Psychobiology
  contributor:
    fullname: Lashley
– volume: 647
  start-page: 106
  year: 1994
  end-page: 112
  ident: bib58
  article-title: Corticosterone enhances long-term retention in one-day-old chicks trained in a weak passive avoidance learning paradigm
  publication-title: Brain Res.
  contributor:
    fullname: Rose
– volume: 26
  start-page: 2254
  year: 1995
  end-page: 2259
  ident: bib71
  article-title: Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence
  publication-title: Stroke
  contributor:
    fullname: Greenlee
– volume: 148
  start-page: 78
  year: 1991
  end-page: 84
  ident: bib27
  article-title: Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Kleinman
– start-page: 87
  year: 2000
  end-page: 90
  ident: bib48
  article-title: Integrating pharmacological and psychosocial treatments for schizophrenia
  publication-title: Acta Psychiatr. Scand. Suppl.
  contributor:
    fullname: Marder
– volume: 155
  start-page: 1080
  year: 1998
  end-page: 1086
  ident: bib34
  article-title: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Davis
– volume: 202
  start-page: 3
  year: 2009
  end-page: 14
  ident: bib49
  article-title: Drug enhancement of memory consolidation: historical perspective and neurobiological implications
  publication-title: Psychopharmacology (Berl.)
  contributor:
    fullname: Roozendaal
– volume: 165
  start-page: 82
  year: 2008
  end-page: 89
  ident: bib8
  article-title: Galantamine for the treatment of cognitive impairments in people with schizophrenia
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: McMahon
– volume: 320
  start-page: 385
  year: 2008
  end-page: 388
  ident: bib67
  article-title: The antidepressant fluoxetine restores plasticity in the adult visual cortex
  publication-title: Science
  contributor:
    fullname: Maffei, L.
– volume: 24
  start-page: 1
  year: 1997
  end-page: 27
  ident: bib46
  article-title: The acute effects of corticosteroids on cognition: integration of animal and human model studies
  publication-title: Brain Res. Brain Res. Rev.
  contributor:
    fullname: McEwen
– volume: 33
  start-page: 465
  year: 2008
  end-page: 472
  ident: bib25
  article-title: A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Johnson
– volume: 138
  start-page: 88
  year: 2012
  end-page: 93
  ident: bib75
  article-title: Developing models of how cognitive impairments change functioning: mediation, moderation and moderated mediation
  publication-title: Schizophr. Res.
  contributor:
    fullname: Landau
– volume: 75
  start-page: 714
  year: 2012
  end-page: 724
  ident: bib44
  article-title: Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model
  publication-title: Neuron
  contributor:
    fullname: Fenton
– volume: 38
  start-page: S21
  year: 2012
  ident: bib26
  article-title: Memory consolidation deficits in schizophrenia and the combination of
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Goff
– volume: 217
  start-page: 855
  year: 1982
  end-page: 857
  ident: bib21
  article-title: Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury
  publication-title: Science
  contributor:
    fullname: Law
– volume: 29
  start-page: 1363
  year: 2004
  end-page: 1373
  ident: bib66
  article-title: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Sahakian
– volume: 56
  start-page: 20
  year: 2004
  end-page: 26
  ident: bib42
  article-title: Levodopa: faster and better word learning in normal humans
  publication-title: Ann. Neurol.
  contributor:
    fullname: Ringelstein
– volume: 25
  start-page: 353
  year: 2010
  end-page: 358
  ident: bib55
  article-title: Use of an acute challenge with
  publication-title: Hum. Psychopharmacol.
  contributor:
    fullname: Maruff
– volume: 23
  start-page: 94
  year: 1988
  end-page: 97
  ident: bib13
  article-title: Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients
  publication-title: Ann. Neurol.
  contributor:
    fullname: Davis
– volume: 64
  start-page: 532
  year: 2007
  end-page: 542
  ident: bib15
  article-title: Overlooking the Obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Gold
– volume: 358
  start-page: 787
  year: 2001
  end-page: 790
  ident: bib59
  article-title: Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study
  publication-title: Lancet
  contributor:
    fullname: Koenig
– volume: 175
  start-page: 501
  year: 2009
  end-page: 509
  ident: bib20
  article-title: Molecular control of brain plasticity and repair
  publication-title: Prog. Brain Res.
  contributor:
    fullname: Fawcett
– volume: 6
  start-page: 61
  year: 2006
  end-page: 67
  ident: bib39
  article-title: Mechanism of action of memantine
  publication-title: Curr. Opin. Pharmacol.
  contributor:
    fullname: Kotermanski
– volume: 37
  start-page: 619
  year: 2011
  end-page: 630
  ident: bib1
  article-title: Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Gleeson
– volume: 342
  start-page: 352
  year: 1985
  end-page: 356
  ident: bib22
  article-title: Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation
  publication-title: Brain Res.
  contributor:
    fullname: Hovda
– volume: 133
  start-page: 833
  year: 2007
  end-page: 858
  ident: bib57
  article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings
  publication-title: Psychol. Bull.
  contributor:
    fullname: Harvey
– volume: 67
  start-page: 674
  year: 2010
  end-page: 682
  ident: bib18
  article-title: Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Keshavan
– volume: 146
  start-page: 553
  year: 1997
  end-page: 559
  ident: bib37
  article-title: Enhancement by an ampakine of memory encoding in humans
  publication-title: Exp. Neurol.
  contributor:
    fullname: Lynch
– volume: 66
  start-page: 839
  year: 2005
  end-page: 843
  ident: bib62
  article-title: Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Schooler
– volume: 37
  start-page: 43
  year: 2012
  end-page: 76
  ident: bib69
  article-title: Cognitive training for impaired neural systems in neuropsychiatric illness
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: de Villers-Sidani
– volume: 7
  start-page: 608
  year: 2006
  end-page: 613
  ident: bib5
  article-title: Treatment of cognitive deficits in schizophrenia
  publication-title: Curr. Opin. Investig. Drugs
  contributor:
    fullname: Harvey
– volume: 36
  start-page: 48
  year: 2010
  end-page: 70
  ident: bib17
  article-title: The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Kreyenbuhl
– volume: 298
  start-page: 358
  year: 1984
  end-page: 361
  ident: bib36
  article-title: Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat
  publication-title: Brain Res.
  contributor:
    fullname: Fenney
– volume: 23
  start-page: 271
  year: 2005
  end-page: 280
  ident: bib56
  article-title: Amphetamine fails to facilitate motor performance and to enhance motor recovery among stroke patients with mild arm paresis: interim analysis and termination of a double blind, randomised, placebo-controlled trial
  publication-title: Restor. Neurol. Neurosci.
  contributor:
    fullname: Kutzner
– volume: 115
  start-page: 55
  year: 2007
  end-page: 59
  ident: bib63
  article-title: Effects of amphetamine and/or
  publication-title: Acta Neurol. Scand.
  contributor:
    fullname: Lokk
– volume: 32
  start-page: 2093
  year: 2001
  end-page: 2098
  ident: bib70
  article-title: A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia
  publication-title: Stroke
  contributor:
    fullname: Unwin
– volume: 67
  start-page: 895
  year: 2010
  end-page: 904
  ident: bib32
  article-title: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Zhao
– volume: 167
  start-page: 170
  year: 2010
  end-page: 180
  ident: bib16
  article-title: A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Bellack
– volume: 66
  start-page: 549
  year: 2009
  end-page: 553
  ident: bib68
  article-title: Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?
  publication-title: Biol. Psychiatry
  contributor:
    fullname: Mellon
– volume: 18
  start-page: 2740
  year: 1998
  end-page: 2747
  ident: bib33
  article-title: Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance
  publication-title: J. Neurosci.
  contributor:
    fullname: Deadwyler
– volume: 213
  start-page: 81
  year: 2012
  end-page: 111
  ident: bib11
  article-title: Towards medication-enhancement of cognitive interventions in schizophrenia
  publication-title: Handb. Exp. Phaermacol.
  contributor:
    fullname: Swerdlow
– volume: 63
  start-page: 1118
  year: 2008
  end-page: 1126
  ident: bib53
  article-title: A meta-analysis of
  publication-title: Biol. Psychiatry
  contributor:
    fullname: Tolin
– volume: 181
  start-page: 144
  year: 2002
  end-page: 152
  ident: bib72
  article-title: Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia
  publication-title: Br. J. Psychiatry
  contributor:
    fullname: Corner
– volume: 168
  start-page: 472
  year: 2011
  end-page: 485
  ident: bib73
  article-title: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Czobor
– volume: 33
  start-page: 1120
  year: 2007
  end-page: 1130
  ident: bib9
  article-title: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Lieberman
– volume: 11
  start-page: 1907
  year: 1991
  end-page: 1917
  ident: bib14
  article-title: The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia
  publication-title: J. Neurosci.
  contributor:
    fullname: Kleinman
– volume: 36
  start-page: 227
  year: 2011
  end-page: 250
  ident: bib23
  article-title: Pharmacological enhancement of memory and executive functioning in laboratory animals
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Jentsch
– volume: 92
  start-page: 519
  year: 2011
  end-page: 530
  ident: bib12
  article-title: Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008
  publication-title: Arch. Phys. Med. Rehabil.
  contributor:
    fullname: Ashman
– volume: 66
  start-page: 811
  year: 2009
  end-page: 822
  ident: bib51
  article-title: Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Glahn
– volume: 130
  start-page: 1
  year: 2011
  end-page: 10
  ident: bib64
  article-title: Are we studying and treating schizophrenia correctly?
  publication-title: Schizophr. Res.
  contributor:
    fullname: Swerdlow
– volume: 33
  start-page: 1477
  year: 2007
  end-page: 1502
  ident: bib50
  article-title: Modafinil: a review of neurochemical actions and effects on cognition
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Carter
– volume: 26
  start-page: 119
  year: 2000
  ident: 10.1016/j.euroneuro.2013.03.012_bib30
  article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
  publication-title: Schizophr. Bull.
  doi: 10.1093/oxfordjournals.schbul.a033430
  contributor:
    fullname: Green
– volume: 77
  start-page: 43
  year: 2005
  ident: 10.1016/j.euroneuro.2013.03.012_bib3
  article-title: Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2004.12.019
  contributor:
    fullname: Barch
– volume: 647
  start-page: 106
  year: 1994
  ident: 10.1016/j.euroneuro.2013.03.012_bib58
  article-title: Corticosterone enhances long-term retention in one-day-old chicks trained in a weak passive avoidance learning paradigm
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(94)91404-4
  contributor:
    fullname: Sandi
– volume: 23
  start-page: 94
  year: 1988
  ident: 10.1016/j.euroneuro.2013.03.012_bib13
  article-title: Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.410230117
  contributor:
    fullname: Crisostomo
– ident: 10.1016/j.euroneuro.2013.03.012_bib52
– volume: 66
  start-page: 549
  year: 2009
  ident: 10.1016/j.euroneuro.2013.03.012_bib68
  article-title: Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2009.02.017
  contributor:
    fullname: Vinogradov
– volume: 3
  start-page: 159
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib31
  article-title: Stimulating the development of drug treatments to improve cognition in schizophrenia
  publication-title: Annu. Rev. Clin. Psychol.
  doi: 10.1146/annurev.clinpsy.3.022806.091529
  contributor:
    fullname: Green
– volume: 65
  start-page: 577
  year: 2009
  ident: 10.1016/j.euroneuro.2013.03.012_bib4
  article-title: Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.21597
  contributor:
    fullname: Berthier
– year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib41
  article-title: Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Keefe
– volume: 63
  start-page: 1118
  year: 2008
  ident: 10.1016/j.euroneuro.2013.03.012_bib53
  article-title: A meta-analysis of d-Cycloserine and the facilitation of fear extinction and exposure therapy
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2008.01.012
  contributor:
    fullname: Norberg
– volume: 38
  start-page: S21
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib26
  article-title: Memory consolidation deficits in schizophrenia and the combination of d-cycloserine with cognitive remediation
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Goff
– volume: 64
  start-page: 168
  year: 2013
  ident: 10.1016/j.euroneuro.2013.03.012_bib61
  article-title: Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2012.07.011
  contributor:
    fullname: Scoriels
– volume: 131
  start-page: 69
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib28
  article-title: d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2011.05.029
  contributor:
    fullname: Gottlieb
– volume: 56
  start-page: 20
  year: 2004
  ident: 10.1016/j.euroneuro.2013.03.012_bib42
  article-title: Levodopa: faster and better word learning in normal humans
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.20125
  contributor:
    fullname: Knecht
– volume: 175
  start-page: 501
  year: 2009
  ident: 10.1016/j.euroneuro.2013.03.012_bib20
  article-title: Molecular control of brain plasticity and repair
  publication-title: Prog. Brain Res.
  doi: 10.1016/S0079-6123(09)17534-9
  contributor:
    fullname: Fawcett
– volume: 133
  start-page: 833
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib57
  article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings
  publication-title: Psychol. Bull.
  doi: 10.1037/0033-2909.133.5.833
  contributor:
    fullname: Reichenberg
– volume: 342
  start-page: 352
  year: 1985
  ident: 10.1016/j.euroneuro.2013.03.012_bib22
  article-title: Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(85)91135-7
  contributor:
    fullname: Feeney
– volume: 146
  start-page: 553
  year: 1997
  ident: 10.1016/j.euroneuro.2013.03.012_bib37
  article-title: Enhancement by an ampakine of memory encoding in humans
  publication-title: Exp. Neurol.
  doi: 10.1006/exnr.1997.6581
  contributor:
    fullname: Ingvar
– volume: 155
  start-page: 1080
  year: 1998
  ident: 10.1016/j.euroneuro.2013.03.012_bib34
  article-title: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites
  publication-title: Am. J. Psychiatry
  doi: 10.1176/ajp.155.8.1080
  contributor:
    fullname: Harvey
– volume: 171
  start-page: 365
  year: 2004
  ident: 10.1016/j.euroneuro.2013.03.012_bib38
  article-title: A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-003-1672-y
  contributor:
    fullname: Jaskiw
– volume: 67
  start-page: 674
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib18
  article-title: Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2010.63
  contributor:
    fullname: Eack
– volume: 36
  start-page: 227
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib23
  article-title: Pharmacological enhancement of memory and executive functioning in laboratory animals
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2010.158
  contributor:
    fullname: Floresco
– volume: 165
  start-page: 82
  year: 2008
  ident: 10.1016/j.euroneuro.2013.03.012_bib8
  article-title: Galantamine for the treatment of cognitive impairments in people with schizophrenia
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2007.07050724
  contributor:
    fullname: Buchanan
– volume: 167
  start-page: 170
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib16
  article-title: A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2009.09020264
  contributor:
    fullname: Dickinson
– volume: 115
  start-page: 55
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib63
  article-title: Effects of amphetamine and/or l-dopa and physiotherapy after stroke—a blinded randomized study
  publication-title: Acta Neurol. Scand.
  doi: 10.1111/j.1600-0404.2006.00728.x
  contributor:
    fullname: Sonde
– volume: 79
  start-page: 1047
  year: 1998
  ident: 10.1016/j.euroneuro.2013.03.012_bib29
  article-title: Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study
  publication-title: Arch. Phys. Med. Rehabil.
  doi: 10.1016/S0003-9993(98)90169-1
  contributor:
    fullname: Grade
– volume: 24
  start-page: 1
  year: 1997
  ident: 10.1016/j.euroneuro.2013.03.012_bib46
  article-title: The acute effects of corticosteroids on cognition: integration of animal and human model studies
  publication-title: Brain Res. Brain Res. Rev.
  doi: 10.1016/S0165-0173(97)00004-0
  contributor:
    fullname: Lupien
– volume: 23
  start-page: 271
  year: 2005
  ident: 10.1016/j.euroneuro.2013.03.012_bib56
  article-title: Amphetamine fails to facilitate motor performance and to enhance motor recovery among stroke patients with mild arm paresis: interim analysis and termination of a double blind, randomised, placebo-controlled trial
  publication-title: Restor. Neurol. Neurosci.
  contributor:
    fullname: Platz
– volume: 7
  start-page: 608
  year: 2006
  ident: 10.1016/j.euroneuro.2013.03.012_bib5
  article-title: Treatment of cognitive deficits in schizophrenia
  publication-title: Curr. Opin. Investig. Drugs
  contributor:
    fullname: Bowie
– volume: 51
  start-page: 59
  year: 2002
  ident: 10.1016/j.euroneuro.2013.03.012_bib10
  article-title: Modulation of use-dependent plasticity by d-amphetamine
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.10056
  contributor:
    fullname: Bütefisch
– volume: 32
  start-page: 2093
  year: 2001
  ident: 10.1016/j.euroneuro.2013.03.012_bib70
  article-title: A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia
  publication-title: Stroke
  doi: 10.1161/hs0901.095720
  contributor:
    fullname: Walker-Batson
– volume: 181
  start-page: 144
  year: 2002
  ident: 10.1016/j.euroneuro.2013.03.012_bib72
  article-title: Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia
  publication-title: Br. J. Psychiatry
  contributor:
    fullname: Wykes
– volume: 33
  start-page: 1120
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib9
  article-title: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbm083
  contributor:
    fullname: Buchanan
– volume: 75
  start-page: 714
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib44
  article-title: Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model
  publication-title: Neuron
  doi: 10.1016/j.neuron.2012.06.016
  contributor:
    fullname: Lee
– volume: 12
  start-page: 206
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib19
  article-title: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin
  publication-title: Mol. Psychiatry
  doi: 10.1038/sj.mp.4001907
  contributor:
    fullname: Ehrenreich
– volume: 168
  start-page: 472
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib73
  article-title: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2010.10060855
  contributor:
    fullname: Wykes
– volume: 25
  start-page: 353
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib55
  article-title: Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia
  publication-title: Hum. Psychopharmacol.
  doi: 10.1002/hup.1118
  contributor:
    fullname: Pietrzak
– start-page: 87
  year: 2000
  ident: 10.1016/j.euroneuro.2013.03.012_bib48
  article-title: Integrating pharmacological and psychosocial treatments for schizophrenia
  publication-title: Acta Psychiatr. Scand. Suppl.
  contributor:
    fullname: Marder
– volume: 18
  start-page: 2740
  year: 1998
  ident: 10.1016/j.euroneuro.2013.03.012_bib33
  article-title: Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.18-07-02740.1998
  contributor:
    fullname: Hampson
– volume: 6
  start-page: 61
  year: 2006
  ident: 10.1016/j.euroneuro.2013.03.012_bib39
  article-title: Mechanism of action of memantine
  publication-title: Curr. Opin. Pharmacol.
  doi: 10.1016/j.coph.2005.09.007
  contributor:
    fullname: Johnson
– volume: 71
  start-page: 138
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib45
  article-title: A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.08m04666yel
  contributor:
    fullname: Levkovitz
– volume: 66
  start-page: 839
  year: 2005
  ident: 10.1016/j.euroneuro.2013.03.012_bib62
  article-title: Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.v66n0705
  contributor:
    fullname: Sevy
– volume: 130
  start-page: 1
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib64
  article-title: Are we studying and treating schizophrenia correctly?
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2011.05.004
  contributor:
    fullname: Swerdlow
– volume: 33
  start-page: 1477
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib50
  article-title: Modafinil: a review of neurochemical actions and effects on cognition
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1301534
  contributor:
    fullname: Minzenberg
– volume: 138
  start-page: 88
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib75
  article-title: Developing models of how cognitive impairments change functioning: mediation, moderation and moderated mediation
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2012.03.020
  contributor:
    fullname: Wykes
– volume: 334
  start-page: 1731
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib40
  article-title: Fear erasure in mice requires synergy between antidepressant drugs and extinction training
  publication-title: Science
  doi: 10.1126/science.1214592
  contributor:
    fullname: Karpova
– volume: 220
  start-page: 249
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib60
  article-title: Effects of modafinil on cognitive functions in first episode psychosis
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-011-2472-4
  contributor:
    fullname: Scoriels
– volume: 36
  start-page: 48
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib17
  article-title: The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbp115
  contributor:
    fullname: Dixon
– volume: 148
  start-page: 78
  year: 1991
  ident: 10.1016/j.euroneuro.2013.03.012_bib27
  article-title: Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia
  publication-title: Am. J. Psychiatry
  doi: 10.1176/ajp.148.1.78
  contributor:
    fullname: Goldberg
– volume: 358
  start-page: 787
  year: 2001
  ident: 10.1016/j.euroneuro.2013.03.012_bib59
  article-title: Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(01)05966-9
  contributor:
    fullname: Scheidtmann
– volume: 67
  start-page: 895
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib32
  article-title: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2010.105
  contributor:
    fullname: Guo
– volume: 298
  start-page: 358
  year: 1984
  ident: 10.1016/j.euroneuro.2013.03.012_bib36
  article-title: Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(84)91437-9
  contributor:
    fullname: Hovda
– volume: 33
  start-page: 465
  year: 2008
  ident: 10.1016/j.euroneuro.2013.03.012_bib25
  article-title: A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1301444
  contributor:
    fullname: Goff
– volume: 202
  start-page: 3
  year: 2009
  ident: 10.1016/j.euroneuro.2013.03.012_bib49
  article-title: Drug enhancement of memory consolidation: historical perspective and neurobiological implications
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-008-1285-6
  contributor:
    fullname: McGaugh
– volume: 26
  start-page: 2254
  year: 1995
  ident: 10.1016/j.euroneuro.2013.03.012_bib71
  article-title: Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence
  publication-title: Stroke
  doi: 10.1161/01.STR.26.12.2254
  contributor:
    fullname: Walker-Batson
– volume: 64
  start-page: 532
  year: 2007
  ident: 10.1016/j.euroneuro.2013.03.012_bib15
  article-title: Overlooking the Obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archpsyc.64.5.532
  contributor:
    fullname: Dickinson
– volume: 37
  start-page: 310
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib65
  article-title: Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2011.195
  contributor:
    fullname: Swerdlow
– year: 1949
  ident: 10.1016/j.euroneuro.2013.03.012_bib35
  contributor:
    fullname: Hebb
– volume: 11
  start-page: 1907
  year: 1991
  ident: 10.1016/j.euroneuro.2013.03.012_bib14
  article-title: The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.11-07-01907.1991
  contributor:
    fullname: Daniel
– volume: 29
  start-page: 1704
  year: 2004
  ident: 10.1016/j.euroneuro.2013.03.012_bib7
  article-title: d-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300464
  contributor:
    fullname: Breitenstein
– volume: 213
  start-page: 81
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib11
  article-title: Towards medication-enhancement of cognitive interventions in schizophrenia
  publication-title: Handb. Exp. Phaermacol.
  doi: 10.1007/978-3-642-25758-2_4
  contributor:
    fullname: Chou
– volume: 37
  start-page: 619
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib1
  article-title: Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbp129
  contributor:
    fullname: Alvarez-Jiménez
– volume: 4
  start-page: 43
  year: 2010
  ident: 10.1016/j.euroneuro.2013.03.012_bib2
  article-title: Pharmacological strategies for enhancing cognition in schizophrenia
  publication-title: Curr. Top. Behav. Neurosci.
  doi: 10.1007/7854_2010_39
  contributor:
    fullname: Barch
– volume: 320
  start-page: 385
  year: 2008
  ident: 10.1016/j.euroneuro.2013.03.012_bib67
  article-title: The antidepressant fluoxetine restores plasticity in the adult visual cortex
  publication-title: Science
  doi: 10.1126/science.1150516
  contributor:
    fullname: Vetencourt
– volume: 29
  start-page: 554
  year: 2006
  ident: 10.1016/j.euroneuro.2013.03.012_bib47
  article-title: Ampakines and the threefold path to cognitive enhancement
  publication-title: Trends Neurosci.
  doi: 10.1016/j.tins.2006.07.007
  contributor:
    fullname: Lynch
– volume: 37
  start-page: S80
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib74
  article-title: Thinking about the future cognitive remediation therapy—what works and could we do better?
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbr064
  contributor:
    fullname: Wykes
– volume: 217
  start-page: 855
  year: 1982
  ident: 10.1016/j.euroneuro.2013.03.012_bib21
  article-title: Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury
  publication-title: Science
  doi: 10.1126/science.7100929
  contributor:
    fullname: Feeney
– volume: 37
  start-page: 43
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib69
  article-title: Cognitive training for impaired neural systems in neuropsychiatric illness
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2011.251
  contributor:
    fullname: Vinogradov
– volume: 106
  start-page: 320
  year: 2008
  ident: 10.1016/j.euroneuro.2013.03.012_bib24
  article-title: Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2008.08.012
  contributor:
    fullname: Goff
– volume: 29
  start-page: 1363
  year: 2004
  ident: 10.1016/j.euroneuro.2013.03.012_bib66
  article-title: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300457
  contributor:
    fullname: Turner
– volume: 169
  start-page: 710
  year: 2012
  ident: 10.1016/j.euroneuro.2013.03.012_bib6
  article-title: Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2012.11091337
  contributor:
    fullname: Bowie
– volume: 92
  start-page: 519
  year: 2011
  ident: 10.1016/j.euroneuro.2013.03.012_bib12
  article-title: Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008
  publication-title: Arch. Phys. Med. Rehabil.
  doi: 10.1016/j.apmr.2010.11.015
  contributor:
    fullname: Cicerone
– volume: 1
  start-page: 141
  year: 1917
  ident: 10.1016/j.euroneuro.2013.03.012_bib43
  article-title: The effects of strychnine and caffeine upon the rate of learning
  publication-title: Psychobiology
  doi: 10.1037/h0075094
  contributor:
    fullname: Lashley
– volume: 66
  start-page: 811
  year: 2009
  ident: 10.1016/j.euroneuro.2013.03.012_bib51
  article-title: Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2009.91
  contributor:
    fullname: Minzenberg
SSID ssj0015339
Score 2.2408276
SecondaryResourceType review_article
Snippet Abstract Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The...
Cognitive impairment is a well-documented feature of schizophrenia and represents a major impediment to the functional recovery of patients. The therapeutic...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 790
SubjectTerms Animals
Cognition - drug effects
Cognition Disorders - drug therapy
Cognition Disorders - etiology
Cognition Disorders - rehabilitation
Cognitive ability
Cognitive impairment
Cognitive remediation
Cognitive-enhancing drugs
Combination of cognitive remediation with cognitive-enhancing drugs
Combined Modality Therapy
Evidence-Based Medicine
Humans
Internal Medicine
Performance-Enhancing Substances - therapeutic use
Psychiatry
Remedial Teaching
Schizophrenia
Schizophrenia - physiopathology
Title Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0924977X13001156
https://dx.doi.org/10.1016/j.euroneuro.2013.03.012
https://www.ncbi.nlm.nih.gov/pubmed/23619163
https://search.proquest.com/docview/1426515058
https://search.proquest.com/docview/1500771776
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELYQvXCpWkrbbQtyJcQJdxPbib3cECpaWIEQXdS9WX5kYSs1ILJ72Au_nRnnsUWI9lApUqTEedgznvnifP5MyG6upRtYYZlPRcGkEwNmU-lYUErlnsP3j8dxyLPzfHglTyfZZI0ctXNhkFbZxP46psdo3RzpN63Zv5vN-j8S_HRQaoI_ZADXoOy2hPQHPv3toaN5IJyp9fa4ZFj6CccL9S-ibiRyvERUO035SxnqJQQaM9HxG_K6gZD0sH7Lt2StKDfJ3kWtQb3cp-PVlKpqn-7Ri5U69fIdWY4jTCyvKU6QhMoH2lCIbks6K2n1JwvvAG9GPWQ6CuAWCv52cUEJ2rGOWFHeoGQHHAv3i-uK4sDu6jTF4cdQm3-LXB1_Hx8NWbP-AvMyG8yZ4GHAM2tzr71IIhxUXOc-aOW0LzILcMFN09xnSgaIFEJrb7UACKi5y0Uq3pP1Etr3I6EyWKu4sFYIL_NCOzDHVDmldNDJNFE9krRtbu5qmQ3T8s9-mc5MBs1kEthS3iOqtY1pZ5FC3CuqphNWJjUVN4l55ig9ctBd-cTXDKSRfz_2a-sHBnoi_l6xZXG7gMcB2AF0CLX_S5kM9ZNS6Ac98qF2oq6-KIMDYF18-p_X-0w2eFywAymKX8j6_H5RbANsmrud2C92yKvDk9HwHPejy5-jRwrrG9w
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5ROLQXRN9LoXWlihPWJrZjO9wQKloKrJC6SHuz_MjSrdSAyO5h_33HeS2ooj1UysmxEz9mxp_tmc8AX6QWLrfcUp_yggrHc2pT4WhQSknPcP3j4z7k5ViOrsW3aTbdgJMuFia6Vba2v7HptbVuU4Ztbw7v5vPh9yQuHZSaxgMZxDXyGWwhGshRO7eOz85H4_4wARFNQ7nHBI0FHrl5RQqMmjoyunnxmvA0ZU9NUk-B0HoyOt2B7RZFkuOmoi9hoyhfwcFVQ0O9OiSTdVRVdUgOyNWaoHr1GlaTGimWNyTGSGL7A2m9iG5LMi9J9dAR7yh-jHic7AjiW8z4y9V3SpDe8YgW5Y_I2oFp4X55U5G4t7t-TeIOZGgk4A1cn36dnIxoewUD9SLLF5SzkLPMWum150mNCBXT0getnPZFZhExuFkqfaZEQGPBtfZWc0SBmjnJU_4WNkvs3_dARLBWMW4t517IQjscjplySumgk1miBpB0fW7uGqYN07mg_TT9MJk4TCbBJ2UDUN3YmC6QFE1fUbV6WJnUVMwk5g9ZGcBRX_KRuBmcSf7928-dHBhUxnjCYsvidom_Q7yDABFb_5c8WaRQSlEVBvCuEaK-vZEJB_E63_2f6n2C56PJ5YW5OBuff4AXrL6_I3os7sHm4n5Z7COKWriPrZb8BtAKHO0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treating+impaired+cognition+in+schizophrenia%3A+The+case+for+combining+cognitive-enhancing+drugs+with+cognitive+remediation&rft.jtitle=European+neuropsychopharmacology&rft.au=Michalopoulou%2C+Panayiota+G&rft.au=Lewis%2C+Sh%C3%B4n+W&rft.au=Wykes%2C+Til&rft.au=Jaeger%2C+Judith&rft.date=2013-08-01&rft.issn=0924-977X&rft.volume=23&rft.issue=8&rft.spage=790&rft.epage=798&rft_id=info:doi/10.1016%2Fj.euroneuro.2013.03.012&rft.externalDBID=ECK1-s2.0-S0924977X13001156&rft.externalDocID=1_s2_0_S0924977X13001156
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0924977X%2FS0924977X13X00100%2Fcov150h.gif